TARGET Study Data
The Target Study Data confirms the effectiveness and safety of TheraSphere Y-90 Glass Microspheres in treating hepatocellular carcinoma (HCC). Conducted across eight countries, the study aimed to establish the relationship between Normal Tissue Absorbed Dose (NTAD), Tumor Absorbed Dose (TAD), and various clinical outcomes. The findings confirmed that the tumor absorbed dose was predictive of both response and overall survival, with responders having a 17% higher mean tumor absorbed dose compared to non-responders. The study also demonstrated a median overall survival of 20.3 months and an Objective Response Rate (ORR) of 70.8% for the target lesion and 61.7% for all lesions. Alongside the Legacy Study and the Dosisphere-01 Trial, the Target Study reinforces the relationship between higher tumor absorbed dose and clinical outcomes.